Several studies have reported that SHP2 interacts with dopamine receptor 1 and activates its target ERK signaling pathway during the progression of levodopa-induced dyskinesia.71–73 Hence, SHP2 has a dual role in PD, and its function depends on specific intracellular events. This evidence concerns the gene PTPN11 and drug-induced dyskinesia.